Bristol-Myers Squibb ($BMY) has signed on Northwestern University to partner on some early-stage immunotherapy trials. Bristol-Myers, one of the leaders in the immuno-oncology field, will collaborate with Lurie Cancer Center and NMDTI on new studies related to small, genetically defined patient subpopulations. "Complementing our broad research and development programs through innovative collaborations with partners such as the Lurie Cancer Center and NMDTI has been a fundamental component to our commitment to leading advances in Immuno-Oncology," said Dr. Laura Bessen, head of U.S. Medical, Bristol-Myers Squibb. Release